The performance of companies tied to Viagra's history presents a complex investment landscape. While the initial success generated substantial gains, generic alternatives have significantly diminished sales . Investing in related pharmaceutical companies now requires a careful assessment of patent rights , evolving healthcare shifts , and the possi